Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | GHSR | Q92847 | 3/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21608030 | 1.00 | DRD4 (0.35) | DRD4HRH3SLC6A4APLNRCHRM2 | |
| SCHEMBL21608099 | 0.89 | MAP4K4 (0.33) | HRH3APLNRGHSRMAP4K4 | |
| SCHEMBL21608097 | 0.89 | MAP4K4 (0.33) | HRH3APLNRGHSRMAP4K4 | |
| SCHEMBL21608093 | 0.89 | MAP4K4 (0.33) | HRH3APLNRGHSRMAP4K4 | |
| SCHEMBL21608092 | 0.89 | MAP4K4 (0.33) | HRH3APLNRGHSRMAP4K4 | |
| SCHEMBL21608548 | 0.86 | KDM1A (0.35) | HRH3GHSRDGKZACACB | |
| SCHEMBL21608552 | 0.82 | TRPV6 (0.37) | GHSR | |
| SCHEMBL21608569 | 0.82 | TRPV6 (0.37) | GHSR | |
| SCHEMBL21608568 | 0.82 | TRPV6 (0.37) | GHSR | |
| SCHEMBL21608560 | 0.82 | TRPV6 (0.37) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | DRD4 4569/4885HRH3 3480/4885SLC6A4 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.